List of Excipients in Branded Drug HYDROCORTISONE VALERATE CREAM

Generic Drugs Containing HYDROCORTISONE VALERATE CREAM

Company	Ingredient	NDC	Excipient
Encube Ethicals Inc	hydrocortisone valerate cream	21922-007	CARBOMER HOMOPOLYMER TYPE C
Encube Ethicals Inc	hydrocortisone valerate cream	21922-007	METHYLPARABEN
Encube Ethicals Inc	hydrocortisone valerate cream	21922-007	POLYOXYL 20 CETOSTEARYL ETHER
Encube Ethicals Inc	hydrocortisone valerate cream	21922-007	PROPYLENE GLYCOL
Encube Ethicals Inc	hydrocortisone valerate cream	21922-007	SODIUM LAURYL SULFATE
Encube Ethicals Inc	hydrocortisone valerate cream	21922-007	SODIUM PHOSPHATE, DIBASIC
Encube Ethicals Inc	hydrocortisone valerate cream	21922-007	STEARETH-100

What are the Most Frequently-Used Excipients in HYDROCORTISONE VALERATE CREAM?

# Of NDCs	Excipient
4	CARBOMER HOMOPOLYMER TYPE C
4	METHYLPARABEN
4	POLYOXYL 20 CETOSTEARYL ETHER
4	PROPYLENE GLYCOL
4	SODIUM LAURYL SULFATE
4	SODIUM PHOSPHATE, DIBASIC
4	STEARETH-100

Hydrocortisone Valerate Cream Excipient Strategy and Commercial Opportunities

Last updated: August 14, 2026

Hydrocortisone valerate cream 0.2% is an established prescription topical corticosteroid with limited brand protection, multiple generic-market opportunities, and formulation differentiation centered on vehicle performance rather than active-ingredient exclusivity. The commercial opportunity is strongest in compliant generic supply, pediatric and sensitive-skin positioning, contract manufacturing, private-label dermatology portfolios, and improved sensory or barrier-support vehicles.

What is hydrocortisone valerate cream?

Hydrocortisone valerate cream contains 2 mg of hydrocortisone valerate per gram of product. It is a medium-potency topical corticosteroid used for inflammatory and pruritic corticosteroid-responsive dermatoses, including eczema and dermatitis indications described in product labeling.[1]

Attribute	Commercially relevant detail
Active ingredient	Hydrocortisone valerate
Strength	0.2%, equivalent to 2 mg/g
Dosage form	Topical cream
Regulatory status	Prescription drug in the United States
Therapeutic category	Topical corticosteroid
Primary use	Inflammatory and pruritic dermatoses
Reference product	Westcort cream, historically marketed under NDA 019463
Generic pathway	Abbreviated New Drug Application, subject to product-specific requirements
Biosimilar pathway	Not applicable; hydrocortisone valerate is a small-molecule drug
Main differentiation lever	Vehicle, sensory profile, skin tolerance, packaging, supply reliability, and price

The product is distinct from over-the-counter hydrocortisone 1% cream. A reformulation or lower-strength strategy does not automatically support an over-the-counter switch because the regulatory monograph, labeling, indication, strength, and safety profile must be satisfied separately.[2]

What excipients are used in hydrocortisone valerate cream?

Representative United States hydrocortisone valerate cream formulations use a water-containing emulsion vehicle with fatty alcohols, glycols, surfactants, and a hydrocarbon emollient.[1,3]

Excipient class	Representative excipients	Primary function
Aqueous phase	Purified water	Continuous phase and solvent
Humectant and cosolvent	Propylene glycol	Water retention, solvent capacity, skin feel, preservation support
Emollient and consistency agents	Cetyl alcohol, stearyl alcohol	Viscosity, structure, spreadability, emollience
Emulsifiers	Polysorbate 60, sorbitan monostearate	Emulsion formation and physical stability
Occlusive phase	White petrolatum	Barrier effect, reduced transepidermal water loss, richer skin feel
Active ingredient	Hydrocortisone valerate	Anti-inflammatory corticosteroid

Inactive ingredients can vary by manufacturer. The reference formulation and generic formulations should be compared product by product because the excipient profile affects rheology, release, skin deposition, sensory acceptance, and local tolerability.[1,3]

How does each excipient affect product performance?

Propylene glycol is commercially useful because it supports both active solubilization and moisturization. Its limitation is tolerability. Some patients with compromised skin barriers may experience stinging or irritation, creating an opportunity for reduced-glycol or glycol-free formulations.

Cetyl alcohol and stearyl alcohol provide the structural framework of the cream. They are fatty alcohols, not drying alcohols. Their ratio influences viscosity, whitening during rub-in, residue, and temperature stability.

Polysorbate 60 and sorbitan monostearate create a conventional nonionic emulsifier system. Nonionic emulsifiers are generally preferred for topical corticosteroids because they are compatible with a broad range of active ingredients and are less dependent on pH than ionic systems.

White petrolatum contributes occlusion and barrier protection. A higher petrolatum content may improve performance for xerotic eczema but can reduce cosmetic acceptance because of greasiness and transfer onto clothing.

What excipient strategy is appropriate for hydrocortisone valerate cream?

The best strategy is to preserve the established cream architecture while optimizing one commercial attribute at a time. A wholesale vehicle redesign creates unnecessary bioequivalence and manufacturing risk.

Strategy 1: Maintain the conventional emulsion

A conventional oil-in-water cream using water, propylene glycol, fatty alcohols, nonionic emulsifiers, and petrolatum offers the lowest development risk. It is closest to established products and provides a familiar regulatory and manufacturing profile.

This approach is appropriate for:

• ANDA development focused on low cost
• Hospital and managed-care tenders
• Private-label dermatology products
• Supply-constrained generic markets
• Contract manufacturing programs

Strategy 2: Reduce irritation potential

A reduced-propylene-glycol or glycol-free product could target patients who report burning or stinging with conventional creams. The vehicle would need an alternative solvent or solubilization approach, such as a carefully selected polyol or a different internal phase composition.

The main development issue is not simply physical stability. Hydrocortisone valerate must remain uniformly distributed, chemically stable, and bioavailable at the skin surface. Changes in solvent strength can alter thermodynamic activity and drug release.

Strategy 3: Improve barrier support

A richer vehicle with increased petrolatum or a complementary lipid system could target xerotic eczema and dermatitis. Ceramides, cholesterol, fatty acids, or other barrier-support ingredients may create a differentiated product, but they also introduce formulation complexity and regulatory questions.

A barrier-support version should be positioned carefully. If the product remains a prescription drug with hydrocortisone valerate as the active ingredient, all added ingredients must be justified for safety, quality, and manufacturing consistency. Cosmetic claims cannot substitute for approved drug labeling.

Strategy 4: Improve sensory performance

A lighter, faster-spreading cream can compete against ointments and greasy generic creams. The primary targets are:

• Reduced tack
• Faster rub-in
• Lower residue
• Lower transfer to clothing
• Better washability
• Consistent application from the tube

Sensory gains can support prescriber acceptance and adherence, but they must not compromise drug release or skin delivery.

Strategy 5: Develop a preservative-minimized product

Some conventional topical creams do not require a traditional antimicrobial preservative when the formulation, packaging, water activity, manufacturing process, and microbiological controls provide adequate protection. This is a formulation-specific conclusion, not a general attribute of hydrocortisone valerate cream.

A preservative-minimized product can appeal to sensitive-skin users. It requires robust microbial limits, preservative-effectiveness assessment where applicable, container-closure evaluation, and stability testing under in-use conditions.[4]

What formulations are commercially protected or differentiated?

The formulation itself is the most credible source of differentiation because the hydrocortisone valerate molecule is old and generic competition is established.

Formulation concept	Differentiation potential	Main development risk
Conventional oil-in-water cream	Low to moderate	Price competition
Low-glycol or glycol-free cream	Moderate	Active solubilization and bioequivalence
Higher-petrolatum barrier cream	Moderate	Greasiness, phase stability, user acceptance
Lightweight cream	Moderate	Lower occlusion and altered release
Preservative-minimized cream	Moderate	Microbial control and shelf life
Airless-pump presentation	Moderate	Device compatibility and residual volume
Unit-dose sachet	Low to moderate	Packaging cost and waste
Ceramide-containing cream	Moderate to high	Regulatory positioning and complex composition
Nanoemulsion or advanced delivery system	High technical differentiation	Higher regulatory, scale-up, and CMC burden

A new excipient combination may support formulation patent claims, but patent strength depends on specific composition ranges, performance data, and claim scope. A broad claim covering a standard hydrocortisone valerate cream is unlikely to provide durable protection against established generic vehicles. A narrower patent directed to a defined excipient ratio, particle-size distribution, release profile, or stability result would have a stronger technical basis but a narrower enforcement position.

When does hydrocortisone valerate cream lose exclusivity?

Hydrocortisone valerate cream lost practical market exclusivity long ago. The active ingredient and reference product date to the early generic era of topical corticosteroids, and the United States market contains approved generic products.

Exclusivity category	Current commercial implication
New chemical entity exclusivity	Expired
Orphan-drug exclusivity	Not applicable
Pediatric exclusivity	No material current barrier identified
Reference-product exclusivity	Expired
Active-ingredient patent protection	No practical current barrier for routine generic entry
Formulation patents	Must be checked against current Orange Book listings and patent records
Generic competition	Established
Biosimilar exclusivity	Not applicable

The practical market question is therefore not whether a competitor can enter, but whether it can obtain approval, demonstrate acceptable product performance, secure reliable supply, and win formulary or pharmacy substitution volume.

What is the Orange Book status of hydrocortisone valerate cream?

The Orange Book determines whether a listed drug has patents or exclusivities relevant to an ANDA applicant.[5] Hydrocortisone valerate cream is an old topical product with no apparent remaining reference-product exclusivity barrier. Commercial diligence should focus on the current listing status of each reference product, the availability of a reference standard, therapeutic-equivalence coding, and any patents listed against the specific product.

For a new ANDA, the regulatory work typically includes:

1. Selecting the correct reference listed drug.
2. Matching strength, dosage form, route, and labeling.
3. Establishing pharmaceutical equivalence.
4. Demonstrating bioequivalence under FDA’s product-specific framework.
5. Addressing formulation differences that could affect local delivery.
6. Completing stability, microbiology, and container-closure studies.
7. Demonstrating manufacturing process control.

FDA’s topical dermatological guidance treats local drug delivery as a central scientific issue. A formulation that is pharmaceutically equivalent but materially different in vehicle composition may require more extensive evidence than a close qualitative and quantitative match.[6]

How many patents cover hydrocortisone valerate cream?

No current broad patent barrier is expected to prevent routine generic development. The relevant IP risk is product-specific and may arise from:

• A listed formulation patent
• A vehicle-composition patent
• A controlled-release or delivery-system patent
• A manufacturing-process patent
• A device or container-closure patent
• Trade-secret protection around processing conditions

Because the product is a conventional topical cream, manufacturing know-how can matter more than patent protection. Emulsification temperature, order of addition, shear rate, cooling profile, active incorporation, deaeration, and filling temperature can affect particle distribution, viscosity, assay uniformity, and release.

Are there Paragraph IV challenges or generic litigation?

Paragraph IV exposure depends on whether a relevant patent is listed for the selected reference product. Given the age of hydrocortisone valerate cream and established generic availability, the principal commercial pathway is ordinary ANDA competition rather than a major patent litigation campaign.

A new applicant should still assess:

Risk area	Likely significance
Paragraph IV patent challenge	Low for an old conventional cream, subject to current listings
ANDA litigation	Low to moderate if a formulation patent is listed
Product-liability litigation	Moderate and driven by corticosteroid labeling and use
Trademark litigation	Low after brand entry, but packaging must avoid confusion
Manufacturing dispute	Moderate where the supplier uses proprietary process know-how
Settlement agreement risk	Low absent a live patent dispute

No biosimilar challenge applies. Hydrocortisone valerate is a chemically synthesized small molecule, so competitors enter through generic-drug regulation rather than the biosimilar pathway.

What commercial opportunities exist for hydrocortisone valerate cream?

Generic and private-label supply

The clearest opportunity is a cost-efficient 0.2% cream supplied to wholesalers, pharmacy chains, hospitals, dermatology distributors, and private-label marketers. The product can be bundled with other topical corticosteroids and nonsteroidal eczema products.

Pediatric and sensitive-skin positioning

Hydrocortisone valerate cream may be commercially differentiated through:

• Fragrance-free presentation
• Reduced-irritant vehicle
• Easy-spread cream
• Small tube sizes
• Tamper-evident packaging
• Clear pediatric-use labeling consistent with the approved label

Pediatric positioning must remain within the approved safety and labeling framework. Potency, treatment duration, body-surface area, and occlusion affect topical corticosteroid risk.

Contract manufacturing

A manufacturer with validated semisolid capabilities can offer:

• Development and scale-up
• Clinical and registration batches
• Tube and pump filling
• Stability programs
• Private-label supply
• Alternate-source manufacturing for existing ANDA holders

This opportunity is strongest where customers value supply continuity more than novel IP.

Geographic expansion

The product can be evaluated for Canada, Europe, Latin America, and selected emerging markets, but the regulatory status of hydrocortisone valerate, allowed corticosteroid strengths, labeling requirements, and prescription classification vary by jurisdiction. A United States ANDA does not create automatic approval elsewhere.

The most practical geographic strategy is regional licensing or dossier transfer to local marketing authorization holders. Manufacturing economics, import controls, serialization, language requirements, and local pharmacovigilance obligations determine feasibility.

How does hydrocortisone valerate cream compare with competing topical corticosteroids?

Product	Relative market position	Commercial comparison
Hydrocortisone 1%	Lower-potency, often OTC	Larger consumer market but lower prescription value
Hydrocortisone valerate 0.2%	Medium-potency prescription product	Differentiates through potency and generic availability
Triamcinolone acetonide 0.1%	Broadly used prescription corticosteroid	Larger competitive field and strong generic pricing pressure
Desonide 0.05%	Lower-potency prescription corticosteroid	Pediatric and sensitive-site competition
Betamethasone valerate	Higher-potency corticosteroid options	Competes where stronger anti-inflammatory activity is needed
Fluocinonide	High-potency corticosteroid	Less direct competition because of potency and safety profile

Hydrocortisone valerate occupies a middle position. It can compete where hydrocortisone 1% is insufficient but a higher-potency corticosteroid is unnecessary. The vehicle, tolerability, and prescriber familiarity are more important than molecular novelty.

What generic launch risks exist?

The main risks are commercial and technical:

• Low price ceilings caused by multiple generic suppliers
• Difficulty obtaining consistent active-ingredient supply
• Vehicle differences that affect local bioequivalence
• Tube-filling losses and semisolid manufacturing variability
• Phase separation during stability testing
• Microbial contamination in the aqueous cream
• Low pharmacy margins
• Limited differentiation under automatic substitution
• Regulatory delay caused by incomplete topical-performance data
• Liability exposure from misuse on thin skin or under occlusion

A low-cost conventional formulation is the most defensible first product. A differentiated vehicle should follow only when the sponsor can support a clear clinical, adherence, or sensory advantage.

How strong is the patent estate for hydrocortisone valerate cream?

The patent estate is weak for the active ingredient and conventional cream. Potentially stronger protection may exist around a genuinely differentiated formulation, but the commercial value of that protection depends on whether the product obtains meaningful market share before competing formulations enter.

A strong development package would combine:

• Narrow, defensible composition claims
• Demonstrated stability advantages
• Superior sensory data
• Consistent in vitro release
• Adequate local bioequivalence evidence
• A scalable manufacturing process
• Proprietary packaging or delivery features where justified

The most valuable asset may be a reliable, low-cost manufacturing process rather than a broad formulation patent.

Key Takeaways

• Hydrocortisone valerate cream 0.2% is an established prescription topical corticosteroid with expired practical market exclusivity.
• The core vehicle commonly uses water, propylene glycol, cetyl alcohol, stearyl alcohol, nonionic emulsifiers, and white petrolatum.
• Commercial differentiation should focus on tolerability, spreadability, barrier support, packaging, and supply reliability.
• A conventional generic cream offers the lowest regulatory and manufacturing risk.
• Reduced-glycol, preservative-minimized, lightweight, and barrier-support vehicles offer higher differentiation but require stronger CMC and topical-performance evidence.
• Biosimilar risk does not apply.
• Paragraph IV and patent-litigation risk appear limited for a conventional product, subject to current Orange Book records.
• The strongest commercial channels are generic supply, private label, contract manufacturing, dermatology portfolios, and regional licensing.

FAQs

Is hydrocortisone valerate cream available over the counter?

No. Hydrocortisone valerate cream 0.2% is generally marketed as a prescription topical corticosteroid in the United States. It is not equivalent to over-the-counter hydrocortisone 1% cream.

Can a glycol-free hydrocortisone valerate cream obtain generic approval?

Yes, but the applicant must demonstrate that the altered vehicle does not adversely affect product quality, local drug delivery, stability, or bioequivalence. A glycol-free formulation is not automatically substitutable with the reference product.

Which packaging is best for hydrocortisone valerate cream?

Aluminum or laminate tubes remain commercially practical because they limit contamination and support controlled dispensing. Airless pumps may improve hygiene and dosing but add device, compatibility, and cost requirements.

Can ceramides be added to hydrocortisone valerate cream?

Ceramides can be evaluated as barrier-support excipients, but they increase formulation and regulatory complexity. The sponsor must establish compatibility, uniformity, stability, microbiological quality, and appropriate labeling.

Is hydrocortisone valerate cream suitable for a dermatology product portfolio?

Yes. It can complement lower-potency hydrocortisone, desonide, triamcinolone, emollients, cleansers, and nonsteroidal topical products. Portfolio value depends on manufacturing cost, formulary access, and supply reliability.

References

1. DailyMed. (n.d.). Hydrocortisone valerate cream, 0.2% prescribing information. U.S. National Library of Medicine.
2. U.S. Food and Drug Administration. (2022). Over-the-counter monograph M017: Topical antimicrobial and analgesic products; hydrocortisone-related monograph provisions. FDA.
3. U.S. Food and Drug Administration. (n.d.). Inactive Ingredient Database. FDA.
4. U.S. Food and Drug Administration. (2016). Microbiological quality considerations in non-sterile drug manufacturing. FDA.
5. U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
6. U.S. Food and Drug Administration. (2022). Draft guidance for industry: Topical dermatological drug product NDAs and ANDAs: In vivo bioequivalence studies and in vitro release tests. FDA.